<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00802841</url>
  </required_header>
  <id_info>
    <org_study_id>CAMN107A2404</org_study_id>
    <secondary_id>2008-007054-35</secondary_id>
    <nct_id>NCT00802841</nct_id>
  </id_info>
  <brief_title>Randomized Phase Lll Study of Imatinib Dose Optimization vs Nilotinib in CML Patients With Suboptimal Response to Imatinib</brief_title>
  <acronym>LASOR</acronym>
  <official_title>A Randomized Phase Lll Study of Imatinib Dose Optimization Compared With Nilotinib in Patients With Chronic Myelogenous Leukemia and Suboptimal Response to Standard-dose Imatinib</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is no available data on the clinical benefit of dose escalation for patients with
      suboptimal response to imatinib, and patients may still improve their response with
      continuation of therapy at the standard dose as shown in the IRIS trial after 5 years of
      follow-up. However, there is no data yet regarding the potential benefit of using nilotinib
      in the group of patients with suboptimal response. In this study, the efficacy of nilotinib
      400mg BID will be compared to imatinib 600mg QD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The comparative efficacy between imatinib dose escalation (600 mg QD) and nilotinib (400 mg
      BID), in terms of CCyR after 6 months, for patients with CML in chronic phase with suboptimal
      response to imatinib standard dose will be determined.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Complete Cytogenetic Response (CCyR)</measure>
    <time_frame>6 months</time_frame>
    <description>CCyR was assessed from bone marrow samples. CCyr was defined as having 0% Philadelphia positive (Ph+) chromosome metaphases in bone marrow.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Major Molecular Response (MMR)</measure>
    <time_frame>12 and 24 months</time_frame>
    <description>MMR was defined as having a fusion gene of the Bcr and Abl genes of (BCR-ACL) less than or equal to 0.1% on the International Scale (IS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With CCyr</measure>
    <time_frame>12 and 24 months</time_frame>
    <description>CCyR was assessed from bone marrow samples. CCyr was defined as having 0% Philadelphia positive (Ph+) chromosome metaphases in bone marrow.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to CCyR</measure>
    <time_frame>24 months</time_frame>
    <description>Time to CCyR was defined as time from date of randomization to date of first documented CCyR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of CCyR</measure>
    <time_frame>24 months</time_frame>
    <description>Duration of CCyR was defined as time from the date of ransomization to the date of first loss of CCyR or death, whichever came first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>24 months</time_frame>
    <description>PFS was defined as the time from the date of randomization to the date of documented disease progression to accelerated phase or blast crisis (AP/BC), or death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-Free Survival (EFS)</measure>
    <time_frame>24 months</time_frame>
    <description>EFS was defined as the time from the date of randomization to the date of the first occurrence of any of the following: loss of Complete Hematological Response (CHR), loss of Partial Cytogenetic Response (PCyR), loss of CCyR, death on treatment or progression to AP/BC.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>24 months</time_frame>
    <description>OS was defined as time from date of randomization to the date of the death.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">191</enrollment>
  <condition>Chronic Myelogenous Leukemia</condition>
  <arm_group>
    <arm_group_label>Nilotinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 400 mg nilotinib twice daily (BID).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Imatinib</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants received 600 mg imatinib once daily (QD).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nilotinib</intervention_name>
    <description>Supplied as 200 mg tablets</description>
    <arm_group_label>Nilotinib</arm_group_label>
    <other_name>Tasigna</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>imatinib</intervention_name>
    <description>Supplied as 100 mg and 400 mg tablets</description>
    <arm_group_label>Imatinib</arm_group_label>
    <other_name>Gleevec/Glivec</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Male or female ≥ 18 years old;

          2. ECOG of 0, 1, or 2;

          3. Ph+ CML in CP defined as:

               -  &lt;15% blasts in peripheral blood or bone marrow;

               -  &lt;30% blasts + promyelocytes in peripheral blood or bone marrow;

               -  &lt;20% basophils in the peripheral blood;

                  •≥100x109/L (≥ 100,000/mm3) platelets;

               -  no evidence of extramedullary leukemia involvement, with the exception of
                  hepatosplenomegaly;

          4. SoR to 400 mg imatinib, defined as (min of 20 metaphases):

               -  No cytogenetic response at ≥ 3 to &lt;6 months (&gt; 95% Ph+ metaphases);or

               -  No PCyR at ≥ 6 to &lt;12 months (36 to 95% Ph+ metaphases on bone marrow); or

               -  No CCyR at ≥ 12 to &lt;18 months (1 to 35% Ph+ metaphases on bone marrow);
                  Confirmation of SoR by FISH is allowed if BMK is done outside the screening
                  window up to 4 wks.

          5. 400mg/daily imatinib (no higher doses) for at least 3months but no longer than 18
             months;

          6. Previous use of IFN, taken prior to imatinib treatment, is allowed at a maximum of 90
             days unless reason for switch from IFN to imatinib was intolerance.

          7. Parameters must be present:

               -  Creatinine &lt;2.0 X ULN

               -  Total bilirubin &lt;1.5 X ULN (&lt; 3.0 X ULN if related to disease);

               -  SGOT and SGPT &lt; 2.5 X ULN;

               -  Serum lipase ≤1.5 X ULN;

               -  Alkaline phosphatase ≤2.5 X ULN

               -  Serum potassium, phosphorus, magnesium and calcium ≥ LLN or corrected to WNL with
                  supplements prior to first dose of study drug;

          8. Written informed consent prior to any study procedures being performed.

        Exclusion criteria:

          1. Prior accelerated phase including clonal evolution or blast crisis CML;

          2. Prior therapy with imatinib in combination with any other CML drug other than
             Hydroxyurea and/or Anagrelide;

        4.Imatinib therapy started more than 12 months after the date of the original diagnosis;
        5.Unable to tolerate imatinib at 400mg; 6.Previous treatment with any other tyrosine kinase
        inhibitor except Glivec and/or CML therapy other than IFN, hydroxyurea, and /or anagrelide;
        7.Myelotoxicity ≥ Grade 2 present at the time of randomization, 8.Previously documented
        T315I mutations; 9.Impaired cardiac function including one of these:

          -  Long QT syndrome or family history of long QT syndrome

          -  Clinically significant resting brachycardia (&lt;50 bpm)

          -  QTcF &gt;450 msec on screening ECG (using the QTcF formula). If QTc &gt;450 and electrolytes
             are not with normal ranges, electrolytes should be corrected and then the patient
             rescreened for QTc to certify QTc &lt;450 msec;

          -  Myocardial infarction ≤ 12 months prior to the first dose of study drug;

          -  Other clinically significant heart disease (e.g., CHF, uncontrolled hypertension,
             unstable angina, significant ventricular or atrial tachyarrhythmias) 10. Impairment of
             GI function or disease that may significantly alter the absorption of study drug; 11.
             Treated with strong CYP3A4 inhibitors that cannot be either discontinued or switched
             to a different medication prior to starting study drug; 12.Currently receiving
             treatment with any medications that have the potential to prolong the QT interval and
             the treatment cannot be either discontinued or switched to a different medication
             prior to starting study drug; 13.History of previous acute pancreatitis within one
             year of study entry or medical history of chronic pancreatitis; 14.Known
             cytopathologically confirmed CNS 15.Women who are pregnant, breast feeding or of a
             childbearing potential without a negative urine pregnancy test at screening. Female
             patients of childbearing potential unwilling to use effective contraceptive
             precautions throughout the trial and for 3 months post trial end. Post-menopausal
             women must be ammenorrheic for at least 12 months to be considered of non-childbearing
             potential; 16. History of another primary malignancy that is currently clinically
             significant or currently requires active intervention; 17.Any other clinically
             significant medical or surgical condition which, according to investigators'
             discretion, should preclude participation; 18.Use of investigational agent within 28
             days prior to enrollment; 19.Patients unwilling or unable to comply with the protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Caba</city>
        <state>Buenos Aires</state>
        <zip>C1221ADC</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Caba</city>
        <state>Buenos Aires</state>
        <zip>C1426ANZ</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>La Plata</city>
        <state>Buenos Aires</state>
        <zip>B1900AWT</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rio Negro</city>
        <state>Viedma</state>
        <zip>8500</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Belo Horizonte</city>
        <state>MG</state>
        <zip>30130-100</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cuiaba</city>
        <state>MG</state>
        <zip>78025-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Curitiba</city>
        <state>PR</state>
        <zip>80060-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Londrina</city>
        <state>PR</state>
        <zip>86015-520</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rio de Janeiro</city>
        <state>RJ</state>
        <zip>20211-030</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rio de Janeiro</city>
        <state>RJ</state>
        <zip>20230-130</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Porto Alegre</city>
        <state>RS</state>
        <zip>91350-200</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Florianopolis</city>
        <state>SC</state>
        <zip>88034-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Campinas</city>
        <state>SP</state>
        <zip>13083-970</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Jaú</city>
        <state>SP</state>
        <zip>17210-080</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <zip>05403-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>São Paulo</city>
        <state>SP</state>
        <zip>01224-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>São Paulo</city>
        <state>SP</state>
        <zip>05651-901</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>São Paulo</city>
        <state>SP</state>
        <zip>08270-070</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210029</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300020</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Beijing</city>
        <zip>100044</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fuzhou</city>
        <zip>350001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shanghai</city>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bogota</city>
        <state>Cundinamarca</state>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Monteria</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Guatemala City</city>
        <zip>01010</zip>
        <country>Guatemala</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hyderabad</city>
        <state>Andhra Pradesh</state>
        <zip>500018</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>560 095</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vellore</city>
        <state>Tamil Nadu</state>
        <zip>632004</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ahmedabad</city>
        <zip>380016</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mumbai 400 020</city>
        <zip>014</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mumbai</city>
        <zip>400 012</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>New Delhi</city>
        <zip>110 029</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mexico</city>
        <state>Distrito Federal</state>
        <zip>06726</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>México</city>
        <state>Distrito Federal</state>
        <zip>02990</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>México</city>
        <state>Distrito Federal</state>
        <zip>06720</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>México</city>
        <state>Distrito Federal</state>
        <zip>14080</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Zapopan</city>
        <state>Jalisco</state>
        <zip>45170</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo León</state>
        <zip>64020</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Panama City</city>
        <state>Panamá</state>
        <country>Panama</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kraków</city>
        <zip>31-501</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-367</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ekaterinburg</city>
        <zip>620102</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Krasnoyarsk</city>
        <zip>680022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moscow</city>
        <zip>125167</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moscow</city>
        <zip>129110</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>N.Novgorod</city>
        <zip>603126</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Perm</city>
        <zip>614068</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rostov-on-Don</city>
        <zip>344090</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>197341</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>St Petersburg</city>
        <zip>191024</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Volgograd</city>
        <zip>400138</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Caracas</city>
        <state>Distrito Capital</state>
        <zip>1010</zip>
        <country>Venezuela</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Maracaibo</city>
        <state>Estado Zulia</state>
        <zip>4004</zip>
        <country>Venezuela</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Brazil</country>
    <country>China</country>
    <country>Colombia</country>
    <country>Germany</country>
    <country>Guatemala</country>
    <country>India</country>
    <country>Mexico</country>
    <country>Panama</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Venezuela</country>
  </location_countries>
  <removed_countries>
    <country>Chile</country>
    <country>Costa Rica</country>
    <country>Finland</country>
    <country>Peru</country>
    <country>Uruguay</country>
  </removed_countries>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 3, 2008</study_first_submitted>
  <study_first_submitted_qc>December 4, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 5, 2008</study_first_posted>
  <results_first_submitted>July 15, 2015</results_first_submitted>
  <results_first_submitted_qc>October 15, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 16, 2015</results_first_posted>
  <last_update_submitted>October 15, 2015</last_update_submitted>
  <last_update_submitted_qc>October 15, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 16, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic</keyword>
  <keyword>Myelogenous</keyword>
  <keyword>Leukemia</keyword>
  <keyword>CML</keyword>
  <keyword>Chronic Phase</keyword>
  <keyword>Suboptimal Response</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imatinib Mesylate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were randomized in 1:1 ratio to imatinib 600 mg QD or nilotinib 400 mg BID for a 2 year study period.</recruitment_details>
      <pre_assignment_details>Cross-over from one arm to the other was allowed for intolerant patients anytime during treatment, patients who failed to achieve CCyR after 6 months of treatment, loss of response, loss of CHR, loss of best achieved cytogenetic response any time during treatment, or other reason approved by the Study Management Committee.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Nilotinib</title>
          <description>Participants received 400 mg nilotinib twice daily (BID).</description>
        </group>
        <group group_id="P2">
          <title>Imatinib</title>
          <description>Participants receievd 600 mg imatinib once daily (QD).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="96"/>
                <participants group_id="P2" count="95"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Full Analysis Set</title>
              <participants_list>
                <participants group_id="P1" count="96"/>
                <participants group_id="P2" count="95"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Set</title>
              <participants_list>
                <participants group_id="P1" count="96"/>
                <participants group_id="P2" count="93"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Cross-over Set</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="56"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="96"/>
                <participants group_id="P2" count="95"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Administrative problems</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Disease progression</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol deviation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Treatment duration completed</title>
              <participants_list>
                <participants group_id="P1" count="66"/>
                <participants group_id="P2" count="76"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Nilotinib</title>
          <description>Participants received 400 mg nilotinib twice daily (BID).</description>
        </group>
        <group group_id="B2">
          <title>Imatinib</title>
          <description>Participants receievd 600 mg imatinib once daily (QD).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="96"/>
            <count group_id="B2" value="95"/>
            <count group_id="B3" value="191"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.6" spread="14.47"/>
                    <measurement group_id="B2" value="44.2" spread="15.02"/>
                    <measurement group_id="B3" value="44.4" spread="14.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B3" value="112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Complete Cytogenetic Response (CCyR)</title>
        <description>CCyR was assessed from bone marrow samples. CCyr was defined as having 0% Philadelphia positive (Ph+) chromosome metaphases in bone marrow.</description>
        <time_frame>6 months</time_frame>
        <population>Full Analysis Set: The FAS included all participants to whom study treatment had been assigned by randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>Nilotinib</title>
            <description>Participants received 400 mg nilotinib twice daily (BID).</description>
          </group>
          <group group_id="O2">
            <title>Imatinib</title>
            <description>Participants receievd 600 mg imatinib once daily (QD).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Complete Cytogenetic Response (CCyR)</title>
          <description>CCyR was assessed from bone marrow samples. CCyr was defined as having 0% Philadelphia positive (Ph+) chromosome metaphases in bone marrow.</description>
          <population>Full Analysis Set: The FAS included all participants to whom study treatment had been assigned by randomization.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
                <count group_id="O2" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0"/>
                    <measurement group_id="O2" value="42.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3106</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Major Molecular Response (MMR)</title>
        <description>MMR was defined as having a fusion gene of the Bcr and Abl genes of (BCR-ACL) less than or equal to 0.1% on the International Scale (IS).</description>
        <time_frame>12 and 24 months</time_frame>
        <population>Full Analysis Set: The FAS included all participants to whom study treatment had been assigned by randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>Nilotinib</title>
            <description>Participants received 400 mg nilotinib twice daily (BID).</description>
          </group>
          <group group_id="O2">
            <title>Imatinib</title>
            <description>Participants receievd 600 mg imatinib once daily (QD).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Major Molecular Response (MMR)</title>
          <description>MMR was defined as having a fusion gene of the Bcr and Abl genes of (BCR-ACL) less than or equal to 0.1% on the International Scale (IS).</description>
          <population>Full Analysis Set: The FAS included all participants to whom study treatment had been assigned by randomization.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
                <count group_id="O2" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.5"/>
                    <measurement group_id="O2" value="25.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.5"/>
                    <measurement group_id="O2" value="35.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With CCyr</title>
        <description>CCyR was assessed from bone marrow samples. CCyr was defined as having 0% Philadelphia positive (Ph+) chromosome metaphases in bone marrow.</description>
        <time_frame>12 and 24 months</time_frame>
        <population>Full Analysis Set: The FAS included all participants to whom study treatment had been assigned by randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>Nilotinib</title>
            <description>Participants received 400 mg nilotinib twice daily (BID).</description>
          </group>
          <group group_id="O2">
            <title>Imatinib</title>
            <description>Participants receievd 600 mg imatinib once daily (QD).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With CCyr</title>
          <description>CCyR was assessed from bone marrow samples. CCyr was defined as having 0% Philadelphia positive (Ph+) chromosome metaphases in bone marrow.</description>
          <population>Full Analysis Set: The FAS included all participants to whom study treatment had been assigned by randomization.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
                <count group_id="O2" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.1"/>
                    <measurement group_id="O2" value="55.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.0"/>
                    <measurement group_id="O2" value="61.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to CCyR</title>
        <description>Time to CCyR was defined as time from date of randomization to date of first documented CCyR.</description>
        <time_frame>24 months</time_frame>
        <population>Full Analysis Set: The FAS included all participants to whom study treatment had been assigned by randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>Nilotinib</title>
            <description>Participants received 400 mg nilotinib twice daily (BID).</description>
          </group>
          <group group_id="O2">
            <title>Imatinib</title>
            <description>Participants receievd 600 mg imatinib once daily (QD).</description>
          </group>
        </group_list>
        <measure>
          <title>Time to CCyR</title>
          <description>Time to CCyR was defined as time from date of randomization to date of first documented CCyR.</description>
          <population>Full Analysis Set: The FAS included all participants to whom study treatment had been assigned by randomization.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
                <count group_id="O2" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.55" lower_limit="5.52" upper_limit="5.98"/>
                    <measurement group_id="O2" value="5.85" lower_limit="5.59" upper_limit="11.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of CCyR</title>
        <description>Duration of CCyR was defined as time from the date of ransomization to the date of first loss of CCyR or death, whichever came first.</description>
        <time_frame>24 months</time_frame>
        <population>Full Analysis Set: The FAS included all participants to whom study treatment had been assigned by randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>Nilotinib</title>
            <description>Participants received 400 mg nilotinib twice daily (BID).</description>
          </group>
          <group group_id="O2">
            <title>Imatinib</title>
            <description>Participants receievd 600 mg imatinib once daily (QD).</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of CCyR</title>
          <description>Duration of CCyR was defined as time from the date of ransomization to the date of first loss of CCyR or death, whichever came first.</description>
          <population>Full Analysis Set: The FAS included all participants to whom study treatment had been assigned by randomization.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
                <count group_id="O2" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">The median duration of CCyr was not achieved because there were not enough number of events.</measurement>
                    <measurement group_id="O2" value="17.2" lower_limit="17.2">There were not enough events to calculate the upper limit of the 95% Confidence Interval (CI).</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-Free Survival (PFS)</title>
        <description>PFS was defined as the time from the date of randomization to the date of documented disease progression to accelerated phase or blast crisis (AP/BC), or death due to any cause.</description>
        <time_frame>24 months</time_frame>
        <population>Full Analysis Set: The FAS included all participants to whom study treatment had been assigned by randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>Nilotinib</title>
            <description>Participants received 400 mg nilotinib twice daily (BID).</description>
          </group>
          <group group_id="O2">
            <title>Imatinib</title>
            <description>Participants receievd 600 mg imatinib once daily (QD).</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-Free Survival (PFS)</title>
          <description>PFS was defined as the time from the date of randomization to the date of documented disease progression to accelerated phase or blast crisis (AP/BC), or death due to any cause.</description>
          <population>Full Analysis Set: The FAS included all participants to whom study treatment had been assigned by randomization.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
                <count group_id="O2" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">The median PFS time was not achieved.</measurement>
                    <measurement group_id="O2" value="NA">The median PFS time was not achieved.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Event-Free Survival (EFS)</title>
        <description>EFS was defined as the time from the date of randomization to the date of the first occurrence of any of the following: loss of Complete Hematological Response (CHR), loss of Partial Cytogenetic Response (PCyR), loss of CCyR, death on treatment or progression to AP/BC.</description>
        <time_frame>24 months</time_frame>
        <population>Full Analysis Set: The FAS included all participants to whom study treatment had been assigned by randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>Nilotinib</title>
            <description>Participants received 400 mg nilotinib twice daily (BID).</description>
          </group>
          <group group_id="O2">
            <title>Imatinib</title>
            <description>Participants receievd 600 mg imatinib once daily (QD).</description>
          </group>
        </group_list>
        <measure>
          <title>Event-Free Survival (EFS)</title>
          <description>EFS was defined as the time from the date of randomization to the date of the first occurrence of any of the following: loss of Complete Hematological Response (CHR), loss of Partial Cytogenetic Response (PCyR), loss of CCyR, death on treatment or progression to AP/BC.</description>
          <population>Full Analysis Set: The FAS included all participants to whom study treatment had been assigned by randomization.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
                <count group_id="O2" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">The median EFS time was not achieved..</measurement>
                    <measurement group_id="O2" value="24.3" lower_limit="23.8">There were not enough events to calculate the upper limit of the 95% CI.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS)</title>
        <description>OS was defined as time from date of randomization to the date of the death.</description>
        <time_frame>24 months</time_frame>
        <population>Full Analysis Set: The FAS included all participants to whom study treatment had been assigned by randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>Nilotinib</title>
            <description>Participants received 400 mg nilotinib twice daily (BID).</description>
          </group>
          <group group_id="O2">
            <title>Imatinib</title>
            <description>Participants receievd 600 mg imatinib once daily (QD).</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS)</title>
          <description>OS was defined as time from date of randomization to the date of the death.</description>
          <population>Full Analysis Set: The FAS included all participants to whom study treatment had been assigned by randomization.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
                <count group_id="O2" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">The median OS time was not achieved because there were not enough number of events.</measurement>
                    <measurement group_id="O2" value="25.7">The median was estimated, but the standard error could not be estimated due to the limitation of the Kaplan Meier method where there were too few events and the last participant had a death. Therefore, the 95% CI could not be calculated.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Nilotinib</title>
          <description>Participants received 400 mg nilotinib twice daily (BID).</description>
        </group>
        <group group_id="E2">
          <title>Imatinib</title>
          <description>Participants receievd 600 mg imatinib once daily (QD).</description>
        </group>
        <group group_id="E3">
          <title>Cross-over to Nilotinib</title>
          <description>Nilotinib 400 mg BID</description>
        </group>
        <group group_id="E4">
          <title>Cross-over to Imatinib</title>
          <description>600 mg QD</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Tachyarrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Autoimmune thyroiditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hepatitis B</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Malaria antibody test positive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Blast cell crisis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Endometrial cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="80" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="61" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="44" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eyelid oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Papilloedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Periorbital oedema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Anal fissure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Proctalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Tongue haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Generalised oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Animal bite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Bilirubin conjugated increased</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Blood phosphorus decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>White blood cell count increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis</organization>
      <phone>862-778-1873</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

